Overview

* Allogene Q3 net loss narrowed to $41.4 mln from $66.3 mln

* Company advances pivotal Phase 2 ALPHA3 trial for LBCL treatment

* Phase 1 RESOLUTION trial with ALLO-329 in autoimmune diseases is enrolling

Outlook

* ALLO-329 proof-of-concept data anticipated in 1H 2026

* Cash runway projected to extend into 2H 2027

Result Drivers

* OPERATING EXPENSES - Declined to $44.9 mln from $71.7 mln a year ago, with R&D expenses down to $31.2 mln and G&A expenses falling to $13.7 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.19

Q3 Net -$41.40

Income mln

Q3 Basic -$0.19

EPS

Q3 -$44.90

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Allogene Therapeutics Inc ( ALLO ) is $7.50, about 85.2% above its November 5 closing price of $1.11

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)